- Report
- June 2023
- 125 Pages
Asia Pacific
From €1340EUR$1,500USD£1,147GBP
- Report
- June 2023
- 111 Pages
North America
From €1340EUR$1,500USD£1,147GBP
- Report
- June 2023
- 124 Pages
Europe
From €1340EUR$1,500USD£1,147GBP
- Report
- March 2025
- 119 Pages
Global
From €3500EUR$4,196USD£3,099GBP
- Report
- March 2025
- 150 Pages
Global
From €4334EUR$4,850USD£3,708GBP
- Report
- April 2025
- 220 Pages
Global
From €1785EUR$1,997USD£1,527GBP
- Newsletter
- August 2026
- 6 Pages
Global
From €179EUR$200USD£153GBP
- Report
- August 2025
Global
From €4423EUR$4,950USD£3,784GBP
- Report
- June 2025
- 180 Pages
Global
From €3575EUR$4,000USD£3,058GBP
- Report
- April 2025
- 203 Pages
Global
From €4155EUR$4,650USD£3,555GBP
- Report
- March 2025
- 160 Pages
Global
From €4155EUR$4,650USD£3,555GBP
- Report
- March 2025
- 211 Pages
Global
From €4155EUR$4,650USD£3,555GBP
- Report
- February 2025
- 135 Pages
Global
From €4334EUR$4,850USD£3,708GBP
- Report
- December 2024
- 55 Pages
Global
From €2233EUR$2,499USD£1,910GBP
- Report
- October 2024
- 181 Pages
Global
From €4155EUR$4,650USD£3,555GBP
- Report
- September 2024
- 118 Pages
Global
From €4021EUR$4,500USD£3,440GBP
- Report
- February 2024
- 75 Pages
Global
From €4423EUR$4,950USD£3,784GBP
- Report
- October 2023
- 85 Pages
United States
From €4021EUR$4,500USD£3,440GBP
- Report
- August 2023
- 180 Pages
Global
From €3351EUR$3,750USD£2,867GBP
- Report
- July 2023
- 210 Pages
Global
From €4021EUR$4,500USD£3,440GBP

Car T therapies are a type of immunotherapy used to treat certain types of cancer. They involve the use of genetically modified T cells, which are a type of white blood cell, to recognize and attack cancer cells. The T cells are taken from the patient's blood, modified in a laboratory, and then infused back into the patient's body. This type of therapy has been used to treat certain types of leukemia and lymphoma, and is being studied for use in other types of cancer.
Car T therapies are a relatively new type of oncology drug, and the market is still in its early stages. However, the potential of this type of therapy has led to a surge of interest from pharmaceutical companies, investors, and researchers. Companies are investing in research and development to improve the safety and efficacy of these therapies, as well as to expand their use to other types of cancer.
Some of the companies in the Car T therapies market include Novartis, Kite Pharma, Gilead Sciences, Juno Therapeutics, and Celgene. Show Less Read more